FindTrial
Sign In

TP-0903

DRUG2 trials

Sponsors

Sumitomo Pharma America, Inc.

Conditions

Advanced Solid TumorsBRAF-Mutated MelanomaCLLChronic Lymphocytic LeukemiaColorectal CarcinomaEGFR Positive Non-small Cell Lung CancerRecurrent Ovarian CarcinomaSLL

Phase 1

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
CompletedNCT02729298
Sumitomo Pharma America, Inc.Advanced Solid Tumors, BRAF-Mutated Melanoma, Colorectal Carcinoma +2
Start: 2016-12-14End: 2022-06-29Updated: 2023-11-14
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
TerminatedNCT03572634
Sumitomo Pharma America, Inc.Chronic Lymphocytic Leukemia, CLL, SLL +1
Start: 2019-06-10End: 2020-01-21Updated: 2023-11-09

Related Papers

Abstract 2197: The AXL kinase inhibitor, TP-0903, demonstrates efficacy in preclinical models of colorectal cancer independent of KRAS mutation status
Cancer Research2019-07-013 citations
Abstract 2006: Targeting AXL kinase with TP-0903 successfully reverses the mesenchymal phenotype and extends survival in preclinical models of advanced ovarian cancer
Cancer Research2019-07-013 citations
Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer
Cancer Research2019-07-012 citations
Abstract 3969: TP-0903, a potent AXL receptor tyrosine kinase inhibitor, enhances the activity of anti-PD-1 therapy in a metastatic preclinical syngeneic model of breast cancer
Cancer Research2019-07-011 citations
Abstract 3969: TP-0903, a potent AXL receptor tyrosine kinase inhibitor, enhances the activity of anti-PD-1 therapy in a metastatic preclinical syngeneic model of breast cancer
Immunology2019-07-01
Abstract 2006: Targeting AXL kinase with TP-0903 successfully reverses the mesenchymal phenotype and extends survival in preclinical models of advanced ovarian cancer
Tumor Biology2019-07-01
Abstract 2197: The AXL kinase inhibitor, TP-0903, demonstrates efficacy in preclinical models of colorectal cancer independent of KRAS mutation status
Experimental and Molecular Therapeutics2019-07-01
Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer
Experimental and Molecular Therapeutics2019-07-01
S909 AXL‐RTK INHIBITION DIRECTS THE FUNCTIONAL PHENOTYPE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
HemaSphere2019-06-01
YIA19-002: Axl-RTK Inhibition Modulates T Cell Functions and Synergizes With Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
Journal of the National Comprehensive Cancer Network2019-03-08
Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
Biology of Blood and Marrow Transplantation2019-01-313 citations
Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
Blood2018-11-292 citations
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
Journal of Clinical Oncology2018-05-205 citations